ep beat driven better expect
top-line org sale gm expans bp lower
sg yoy beat increas confid
ep beat aid stronger top-line gm expans hsi ep
consensu reflect better anticip organ sale
vs mse/consensu gm bp yoy gm benefit
due favor commod stronger volum progress margin
growth save sg expens also lower expect
sale vs consensu overal longer season benefit sale
bp org sale flat ex-east na organ sale increas strong
volum better yoy price yoy top-line solid
org sale reiter guidanc net sale ii
benefit acquisit iii modest gm expans in-lin
iv ep
expect perform offer greater flexibl achiev target
innov includ stand-up bag start rees thin launch
april mint flavor kit kat expect decemb benefit top-line
throughout year howev expect continu categori soft
chocol sale share loss bp
progress remaind though compani note
share bp season forecast org sale
sale weight due benefit see potenti
downsid risk second half greater elast potenti higher
increas estim reflect beat rais pt flow
beat rais ep vs
prior estim reflect organ sale gm bp
ebit margin bp yoy rais pt
base ep
food unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
risk-reward view fundament advantag reflect valuat
risk-reward view fundament advantag reflect valuat
pt reflect ev/ebitda price-to-earnings premium center
innov favor categori dynam lead upsid increment
innov strong nam confectionari categori growth recoveri
intern result organ sale growth deflationari input cost
moder promot environ lead bp margin expans
base ev/ebitda price-to-earnings
base ev/ebitda price-to-earnings
modest recoveri organ sale modest volum declin off-set strong
price realiz org sale expect na organ growth
acceler recov drive organ sale growth
margin expand ep grow msd
organ sale deceler volum deceler
growth remain weak input cost inflat increas competit promot
pressur result flat yoy ebit margin ep flat
underweight top-line growth
remain tepid face increasingli
difficult top-line growth outlook due
innov pipelin mount us
limit upsid consensu margin
expect cautiou
margin expans prospect
benefit restructur save
favor input cost upsid
constrain greater retail pressur
supplier elev reinvest need
valuat among risk
post-reform tax landscap
project ep ebitda growth
across packag food sector
shift valu premium
weaker expect guidanc
risk achiev price
success innov
exhibit hsi ntm price-to-earnings slightli histor averag
exhibit trade std deviat histor
exhibit ms forecast organ growth nam
exhibit gross margin increas bp
sale
sell market administr
sg sale
provis incom tax
incom oper
loss /incom discontinu oper extraordinari item net tax
fx impact ep
sale
equival
prepaid
accru liabil tax
current portion ltd
net issuanc repurchas common
total liabiltii stockhold equiti
net chang wc
net flow provid use oper activ
dec inc a/r
dec inc inv
dec inc assets/liab
flow provid use invest activ
net flow use invest activ
flow provid use financ activ
proce ipo
net chang short-term borrow
repay long-term debt
exercis stock option
net flow use provid financ activ
chang equival
equival begin period
equival end period
